Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone Dexborneol in Extended Window Stroke (EXISTENT)
NCT04817527Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of edaravone dexborneol in ischemic stroke (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Proportion of patients with modified Rankin Score 0 to 3 at 90 days, Proportion of symptomatic intracranial hemorrhage at 48 hours and 1 more. Status: unknown.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04817527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817527.